Congenital Pseudoarthritis of the Tibia

Showing 1 posts of 1 posts found.

Results from Novadip phase 1b/2a trial reveal 88% efficacy

January 28, 2025
Clinical Research Congenital Pseudoarthritis of the Tibia, Rare Diseases, clinical trials, efficacy, paediatric, rare diseases

Novadip Biosciences, a clinical stage biotechnology company with a specialty in regenerative medicine, has announced the results of its 12-month …

The Gateway to Local Adoption Series

Latest content